文献速递神经肿瘤神经重症

恶性胶质瘤与实体瘤的预立医疗照护计划记录及终末期照护模式比较

Documented advance care planning elements and end-of-life care patterns in malignant glioma vs. major solid tumors: a single-center retrospective study.
PubMed 文献 · J Neurooncol · 2025-12-29

单中心回顾性队列研究比较恶性胶质瘤与五大实体瘤接受姑息治疗会诊患者的终末期照护模式,发现胶质瘤患者预立医疗照护计划记录率显著更低(20.1% vs 58.0%),且更少在护理医院以外场所死亡,提示需早期开展预立医疗照护计划。

要点

  • 恶性胶质瘤患者预立医疗照护计划记录率仅20.1%,显著低于实体瘤的58.0%。
  • 胶质瘤患者生命维持治疗决策由患者本人决定的比例仅21.4%,远低于实体瘤的67.1%。
  • 胶质瘤患者更少使用临终关怀(62.0% vs 73.1%),更多死于护理医院或院外场所。

核心结论

  • 恶性胶质瘤患者预立医疗照护计划记录率显著低于实体瘤患者,且更易死于护理医院。
  • 早期预立医疗照护计划及个体化姑息策略对恶性胶质瘤患者至关重要。

研究设计与样本

  • 单中心回顾性队列研究,纳入韩国三级医院2018至2022年接受姑息治疗会诊的恶性胶质瘤或五大实体瘤成人患者。
  • 恶性胶质瘤229例,实体瘤4283例,临床数据链接至国民健康保险服务数据库。
  • 采用多变量回归分析预立医疗照护计划记录、医疗资源利用及死亡地点。

主要发现

  • 恶性胶质瘤患者预立医疗照护计划记录率20.1%,实体瘤58.0%,aOR 0.13(95% CI 0.09-0.19)。
  • 生命维持治疗决策由患者本人决定的比例胶质瘤21.4%,实体瘤67.1%,aOR 0.07(95% CI 0.04-0.12)。
  • 胶质瘤患者急诊就诊更少(29.3% vs 48.7%),化疗更少(29.7% vs 42.0%),临终关怀使用更低(62.0% vs 73.1%,aOR 0.57,95% CI 0.43-0.77)。
  • 胶质瘤患者死亡前6个月医疗费用更高,但最后1个月更低。
  • 胶质瘤患者更多死于护理医院(20.5% vs 6.8%,p<0.0001)或家庭/非医院场所(15.3% vs 10.0%,p=0.0106)。

临床怎么用

  • 对恶性胶质瘤患者应早期启动预立医疗照护计划讨论,提高患者本人决策记录率。
  • 针对胶质瘤患者神经认知 decline 特点,制定个体化姑息治疗方案并加强临终关怀转介。

局限性

  • 单中心回顾性研究,结果外推需谨慎。
  • 仅纳入接受姑息治疗会诊的患者,存在选择偏倚可能。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Malignant glioma patients face unique end-of-life (EOL) challenges due to their aggressive disease course and early neurocognitive decline. This study aimed to compare EOL patterns between patients with malignant glioma and those with solid tumors referred for palliative care (PC). METHODS: We conducted a retrospective cohort study of adults with malignant glioma or five major solid tumors (lung, colorectal, gastric, liver, and pancreato-biliary) who received PC consultation at a South Korean tertiary hospital (2018-2022). Clinical data were linked to the National Health Insurance Service database. Outcomes included documentation of advance care planning (ACP) elements, healthcare utilization, and place of death, which were analyzed using multivariable regression. RESULTS: Compared with 4,283 individuals with solid tumors, those with malignant glioma (n = 229) were younger and referred to PC earlier. ACP documentation was substantially lower (20.1% vs. 58.0%; aOR, 0.13; 95% CI, 0.09-0.19), and only 21.4% of life-sustaining treatment decisions were documented as patient-determined versus 67.1% in solid tumors (aOR, 0.07; 95% CI, 0.04-0.12). Malignant glioma was also associated with fewer emergency visits (29.3% vs. 48.7%) and less chemotherapy (29.7% vs. 42.0%) but lower hospice use (62.0% vs. 73.1%; aOR, 0.57; 95% CI, 0.43-0.77). Medical costs were higher six months before death but lower in the final month among patients with malignant glioma compared with those with solid tumors. Death occurred more often in nursing care hospitals (20.5% vs. 6.8%, p < 0.0001) or at home/non-hospital settings (15.3% vs. 10.0%, p = 0.0106). CONCLUSION: In this single-center cohort, malignant glioma patients were less likely to have documented ACP elements and more likely to die in nursing hospitals than those with solid tumors. Early ACP and tailored palliative strategies are essential.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Jeung YS, Lee WT, Kim Y, et al. Documented advance care planning elements and end-of-life care patterns in malignant glioma vs. major solid tumors: a single-center retrospective study. J Neurooncol. 2025. PMID: 41460550. doi:10.1007/s11060-025-05396-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。